Plain-English translation of NCT04904146 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a research study that collects blood and tissue samples from patients with mycosis fungoides or Sézary syndrome—two rare types of skin cancer—to identify biological markers (signs in the blood or tissue) that can predict how well a patient will respond to treatment. By studying these markers, researchers hope to better understand which patients are most likely to benefit from specific therapies and improve how doctors personalize care for these conditions.
Current treatments for mycosis fungoides and Sézary syndrome work well for some patients but not others, and doctors don't have reliable ways to predict in advance who will respond. This study aims to discover biological markers that can help doctors identify which patients will benefit most from which treatments, potentially leading to better, more personalized care.
You likely qualify if…
You likely don't qualify if…
As a participant, you would donate blood and possibly tissue samples that researchers will analyze to identify biological markers linked to treatment response. The study does not involve taking a new medication or undergoing a specific treatment—it is observational, meaning researchers are studying existing samples and medical information to learn more about your condition. You would work with the research team at Lund University Hospital, and there are no strict limits on routine lab work or other medical care you may receive.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
Sweden
Sponsor
Lund University Hospital
Enrollment target
~120 participants
Started
April 2021
Primary completion
April 2027
Age range
18 Years – 100 Years
Last updated on clinicaltrials.gov in March 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.